NTLA vs. VIVO, EDIT, CRSP, SGMO, LNTH, NEOG, CLDX, QDEL, MYGN, and ACHV
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Meridian Bioscience (VIVO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Lantheus (LNTH), Neogen (NEOG), Celldex Therapeutics (CLDX), QuidelOrtho (QDEL), Myriad Genetics (MYGN), and Achieve Life Sciences (ACHV). These companies are all part of the "medical" sector.
Intellia Therapeutics (NASDAQ:NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
In the previous week, Intellia Therapeutics had 7 more articles in the media than Meridian Bioscience. MarketBeat recorded 8 mentions for Intellia Therapeutics and 1 mentions for Meridian Bioscience. Intellia Therapeutics' average media sentiment score of 0.77 beat Meridian Bioscience's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.
88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Meridian Bioscience shares are held by institutional investors. 3.0% of Intellia Therapeutics shares are held by insiders. Comparatively, 2.3% of Meridian Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Meridian Bioscience has a net margin of 12.70% compared to Intellia Therapeutics' net margin of 0.00%. Meridian Bioscience's return on equity of 16.74% beat Intellia Therapeutics' return on equity.
Meridian Bioscience has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics currently has a consensus target price of $69.00, suggesting a potential upside of 160.38%. Given Intellia Therapeutics' higher possible upside, equities research analysts plainly believe Intellia Therapeutics is more favorable than Meridian Bioscience.
Intellia Therapeutics received 108 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 69.51% of users gave Intellia Therapeutics an outperform vote while only 49.84% of users gave Meridian Bioscience an outperform vote.
Intellia Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
Summary
Intellia Therapeutics beats Meridian Bioscience on 9 of the 17 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
Free NTLA Stock Alerts